Literature DB >> 7980214

Aspirin reduces the incidence of colonic carcinoma in the dimethylhydrazine rat animal model.

A E Davis1, F Patterson.   

Abstract

BACKGROUND: Epidemiological studies in humans suggest that regular use of non-steroidal anti-inflammatory drugs (NSAIDS) especially aspirin significantly decreases the risk of developing colorectal cancer. AIMS: The purpose of this study was to investigate the effect of aspirin on colonic carcinogenesis using the dimethylhydrazine (DMH) colonic cancer model in rats.
METHODS: Groups of animals were given daily doses of aspirin either 0, 5, 30 or 60 mg/kg for 18 weeks. Half of each group also received 18 x 30 mg/kg/wk injections of DMH.
RESULTS: Aspirin at doses of 5, 30 or 60 mg/kg/dy had a progressive effect on the reduction of tumour numbers and the percentage of tumours greater or equal to 5 mm in diameter. Aspirin at doses of 30 and 60 mg/kg/dy significantly reduced tumour incidence.
CONCLUSION: These findings support the epidemiological studies in humans. The rat DMH model would appear to be suitable for investigating the mechanism of action of aspirin in reducing colonic tumour formation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7980214     DOI: 10.1111/j.1445-5994.1994.tb02176.x

Source DB:  PubMed          Journal:  Aust N Z J Med        ISSN: 0004-8291


  3 in total

Review 1.  Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency.

Authors:  Denis E Corpet; Sylviane Taché
Journal:  Nutr Cancer       Date:  2002       Impact factor: 2.900

2.  Luteolin supplementation adjacent to aspirin treatment reduced dimethylhydrazine-induced experimental colon carcinogenesis in rats.

Authors:  Neamt H A Osman; Usama Z Said; Ahmed M El-Waseef; Esraa S A Ahmed
Journal:  Tumour Biol       Date:  2014-10-24

Review 3.  Selective inhibitors of cyclooxygenase-2. Potential in elderly patients.

Authors:  N M Davies; J L Wallace
Journal:  Drugs Aging       Date:  1996-12       Impact factor: 3.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.